

## Curriculum Vitae

Personal information **Rebecca Cox**

### Work experience

1. Employer: Haukeland University Hospital
  - Start date: 112011
  - End date:
  - Position: Head of Influenza Centre
  - Activities:
  - Country: Norway
2. Employer: University of Bergen
  - Start date: 091995
  - End date:
  - Position: Professor and Head of the Influenza Centre
  - Activities:
  - Country: Norway

### Education and training

1. Subject: The London Hospital Medical College, University of London
  - Start date: 091990
  - End date: 031995
  - Qualification: PhD
  - Organisation: Influenza, vaccine, clinical trials, preclinical, clinical
  - Country: United Kingdom
2. Subject: Plymouth University
  - Start date: 091987
  - End date: 061990
  - Qualification: B.Sc. (Hons) First class Biological Sciences
  - Organisation: Influenza, virology, immunology
  - Country: United Kingdom

### Additional information

#### Publications

175 total publications in high impact international peer reviewed journals 82 publications last 5 years / H-index 42, 10397 citations (Google scholar H index 46, citations 10397) / Complete list of publications can be found [here](#)

#### Projects

Project management experience (Current) Cox has been a partner in 9 EU grants (Framework programmes (FP) 4, 5, 6, 7, H2020, Nanomedicines and Innovative Medicines Initiative (IMI)), 5 Research Council of Norway (RCN) grants and coordinated 3 international consortia funded by RCN and 2 by Helse Vest. She was also a partner in KG Jebsen centre for Influenza Vaccine Research.

Year	Project owner - Project - Role - Funder
2025-27	NORDFORSK, <a href="#">Nordic Post-COVID Economic Impact Consortium</a> Partner. Budget NOK 5 million
2023-26	KLINBEFORSK. <i>Rehabilitation of cognitive decline after COVID-19 (ReCover)</i> Partner. Budget NOK 20 million.
2021-27	EU IMI2 <i>Innovations to accelerate vaccine development vaccine development and manufacture (Inno4Vac)</i> . Grant Number 101007799. 41 partners. WP leader Budget: €18.6 million.
2021-25	EU H2020. <i>European Corona Vaccine Trial Accelerator Platform. (Vaccelerate)</i> . Grant no. 101037867 31 partners. National coordinator &

	WP leader Conducted 3 phase 2 clinical trials. Budget: €12 million.
<b>2020-26</b>	EU H2020 <i>Indo-European Consortium for Next Generation Influenza Vaccine Innovation (INCENTIVE)</i> . 19 partners. PI children's vaccine clinical trial. Budget: €6 million
2020-22	Research Council of Norway (RCN)/Trond Mohn Foundation (TMF). COVID-19 in healthcare workers and the general population in Western Norway. 5 partners. Coordinator - RJ Cox. <b>Project. Budget: NOK 5 million</b>
2020-21	Helse Vest. COVID-19 in healthcare workers and the general population in Western Norway. Grant number F-11628. Coordinator - RJ Cox. <b>Budget: NOK 1.7 million</b>
<b>2019-26</b>	RCN <i>An effectiveness trial (phase IV) to evaluate protection of children and pregnant women by influenza vaccine in rural Bangladesh</i> . Partner icddr,b Coordinator - RJ. Cox. Budget: NOK 16.9 million

#### Memberships

International Society of Respiratory Viruses

Norwegian Society of Immunology

Member of [The Norwegian Academy of Science and Letters](#)

#### Other Relevant Information

Year	Description - Role
2025-	Editorial board Elsevier <a href="#">Vaccine</a> journal ( <i>international</i> )
2024-	EU HERA Group for Identification and Prioritisation (GIP) ( <i>international</i> )
2024-	Advisor for WHO <a href="#">Public Health Research Agenda for Influenza</a> Workstream 3 ( <i>international</i> )
2023-	Member of WHO <a href="#">Technical Advisory Group on a value assessment of influenza vaccines</a> ( <i>international</i> )
2022-	Member of <a href="#">The Norwegian Academy of Science and Letters</a> ( <i>national</i> )
2022-	Member European Medicines Agency <a href="#">Scientific Advisory Group Vaccines</a> ( <i>international</i> )
2021-24	Member European <a href="#">expert group on SARS-CoV-2 variants</a> ( <i>international</i> )
2021	Member of the study group National Academy of Science, Engineering and Medicine (NASEM), USA “ <a href="#">Best practices for vaccine research and development for management of pandemic influenza</a> ” ( <i>international</i> )
2020-	Leader of Bergen COVID-19 consortium, an interdisciplinary consortium in Western Norway responding to the COVID-19 pandemic with >2500 participants ( <i>regional</i> )
2020-	Member of expert group on COVID-19 vaccines providing scientific advice to the Norwegian government ( <i>national</i> )
2020-	Member of expert group of Norwegian National Knowledge programme on COVID-19 providing scientific advice to the Norwegian government ( <i>national</i> )
2020	Scientific advisor to European Commission to assist the

	Group of Chief Scientific Advisors with the development of the policy-based Scientific Opinion on Pandemics ( <i>international</i> )
2020-21	Scientific advisor to UK government on COVID-19 ( <i>international</i> )
2019-	Task force member <a href="#">Influenza Vaccines Research and Development Roadmap</a> (IVR) ( <i>international</i> )
2019-	Deputy chair <a href="#">Influenza and Other Respiratory Viruses</a> (board member since 2009) ( <i>international</i> )
2019-	Member of European infrastructure for translational medicine ( <a href="#">Eatris</a> ) vaccine platform ( <i>network consisting of 80+ top tier centres in EU</i> ) ( <i>international</i> )
2019	Scientific advisor and panel moderator to World Health Organisation (WHO) <a href="#">Technical Consultation on better global tools: Product research and innovation for influenza prevention, control and treatment</a> ( <i>international</i> )
2018-	Senior Editor for the Blackwell journal <a href="#">Influenza and Other respiratory viruses</a> ( <i>international</i> )